{"id":"6mw3211","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL6068290","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thus enhancing the immune response against cancer cells.","oneSentence":"6MW3211 is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:27:36.018Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05448599","phase":"PHASE1, PHASE2","title":"A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-07-08","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT05440045","phase":"PHASE2","title":"A Clinical Study of 6MW3211 in Patients With Renal Cancer","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-09-01","conditions":"Advanced Clear Cell Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT05446688","phase":"PHASE2","title":"A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-09-01","conditions":"Lymphoma","enrollment":40},{"nctId":"NCT05431569","phase":"PHASE2","title":"A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-07-10","conditions":"Advanced Lung Cancer","enrollment":36},{"nctId":"NCT05048160","phase":"PHASE1, PHASE2","title":"A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2021-09-27","conditions":"Advanced Malignant Neoplasm","enrollment":272}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["6MW3211injection","6MW3211 injection"],"phase":"phase_2","status":"active","brandName":"6MW3211","genericName":"6MW3211","companyName":"Mabwell (Shanghai) Bioscience Co., Ltd.","companyId":"mabwell-shanghai-bioscience-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"6MW3211 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}